Evidence map›Paper›PMID 37375311›Full record

ArticleMolecules (Basel, Switzerland)2023

A Rapid Qualitative Screening Method for Isoniazid Tablets Using Handheld NIR Spectrometers in Two Countries.

Matthew Eady, Jonelle Caison, Mohammed Jinnah, David Jenkins

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Matthew EadyFHI 360-Product Quality Compliance Department, Durham, NC 27713, USA.ORCID 0000-0002-3617-6636
Jonelle CaisonFHI 360-Product Quality Compliance Department, Durham, NC 27713, USA.
Mohammed JinnahFHI 360-Product Quality Compliance Department, Centurion 0157, South Africa.
David JenkinsFHI 360-Product Quality Compliance Department, Durham, NC 27713, USA.ORCID 0000-0001-6698-272X

Funding

United States Agency for International Development AID-OAA-C-15-00001
6 · The paper itself

Abstract

backgroundIsoniazid is a leading tuberculosis treating medication. Global supply chains provide essential medicines such as isoniazid to resource-limited areas. Ensuring the safety and efficaciousness of these medicines is essential to public health programs. Handheld spectrometers are becoming increasingly approachable in cost and usability. As supply chains expand, quality compliance screening of essential medications is necessary in site-specific locations. Here, a brand-specific qualitative discrimination analysis of isoniazid is approached by collecting data from two handheld spectrometers in two countries with the intent to build a multi-location quality compliance screening method for a brand of isoniazid.

methodsTwo handheld spectrometers (900-1700 nm) were used to collect spectra from five manufacturing sources (N = 482) in Durham, North Carolina, USA, and Centurion, South Africa. A qualitative brand differentiation method was established from both locations by applying a Mahalanobis distance thresholding method as a measure of assessing similarity.

resultsCombining data from both locations resulted in a 100% classification accuracy, at both locations, for brand 'A' and resulted in the four other brands classifying as dissimilar. Bias was found between sensors in terms of resulting Mahalanobis distances, but the classification method proved to be robust enough to accommodate. Several spectral peaks found in isoniazid references appear within the 900-1700 nm range, as well as variation in the excipients per manufacturer.

conclusionsResults show promise for compliance screening isoniazid as well as other tablets in multiple geographic locations using handheld spectrometers.

Indexed as

IsoniazidSpectroscopy, Near-InfraredCalibrationSouth AfricaTabletsIsoniazidTabletsdiffuse reflectanceglobal healthisoniazidnear-infraredportable spectroscopyquality compliancerapid testingsupply chaintuberculosis

Identifiers

PMID37375311
PMCPMC10305059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.